The Mutual Recognition procedure allows
applicants to obtain a marketing authorization
in the Concerned member states (CMS) other
than the Reference member state (RMS), where
the drug is previously approved.
Medicines officially designated 'Orphan
medicines' (medicines used for rare
diseases